Ticker Details
T2 Biosystems, Inc. T2 Biosystems Inc is an in vitro diagnostic company. It has developed the proprietary platform that enables direct detection of pathogens, biomarkers and other abnormalities across various unpurified patient sample types.
IPO Date:	August 7, 2014
Sector:	Healthcare
Industry:	Medical Diagnostics and Research
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.17 | 4.83%
Avg Daily Range (30 D):	$0.01 | 62.50%
Avg Daily Range (90 D):	$0.02 | 71.43%

Institutional Daily Volume
Avg Daily Volume:	5.69M
Avg Daily Volume (30 D):	.03M
Avg Daily Volume (90 D):	.02M

Trade Size
Avg Trade Size (Sh.):	926
Avg Trade Size (Sh.) (30 D):	3,012
Avg Trade Size (Sh.) (90 D):	2,519

Institutional Trades
Total Institutional Trades:	103
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$.51M
Avg Institutional Trade (90 D):	$.51M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.16M
Avg Closing Trade (30 D):	$.51M
Avg Closing Trade (90 D):	$.51M
Avg Closing Volume:	21.44K

News

Feb 3, 2026 @ 3:51 PM T2 Biosystems, Inc. Announces Intent to Complete W... Source: Prnewswire

Jul 16, 2025 @ 1:00 PM Vivid Dx Appoints Diagnostics Veteran John Sperzel... Source: Globe Newswire

Jul 22, 2024 @ 8:39 PM T2 Biosystems to Report Second Quarter 2024 Financ... Source: N/A

May 22, 2024 @ 1:00 PM T2 Biosystems Regains Compliance with Nasdaq Conti... Source: T2 Biosystems, Inc.

May 17, 2024 @ 8:05 PM T2 Biosystems Announces Closing of $8 Million Priv... Source: T2 Biosystems, Inc.

Financials
	TTM	Q2 2024	Q1 2024
Basic EPS	$-.57	$-.64	$-2.66
Diluted EPS	$-.57	$-.64	$-2.66
Revenue	$1.99M	$1.95M	$2.06M
Gross Profit
Net Income / Loss	$-10.12M	$-8.96M	$-13.53M
Operating Income / Loss	$-10.16M	$-9.58M	$-12.6M
Cost of Revenue
Net Cash Flow	$M	$M	$M
PE Ratio